InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.